New Hampshire § 126-Z:2 Availability of Investigational Drugs, Biologics, or Devices;  Costs;  Coverage

New Hampshire Statutes

§ 126-Z:2 — Availability of Investigational Drugs, Biologics, or Devices; Costs; Coverage

New Hampshire § 126-Z:2

Title XPUBLIC HEALTH

Ch. 126-ZRIGHT TO TRY ACT

This text of New Hampshire § 126-Z:2 (Availability of Investigational Drugs, Biologics, or Devices; Costs; Coverage) is published on Counsel Stack Legal Research, covering New Hampshire primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

N.H. Rev. Stat. Ann. § 126-Z:2 (2026).

Text

I. A manufacturer of an investigational drug, biologic, or device may make available an investigational drug, biologic, or device to eligible patients pursuant to this chapter. A manufacturer may:

(a)Provide an investigational drug, biologic, or device to an eligible patient without receiving compensation.

(b)Require an eligible patient to pay the costs of or associated with the manufacture of the investigational drug, biologic, or device.

(c)Require an eligible patient to participate in data collection relating to the use of the investigational drug, biologic, or device. II. This chapter shall not require a health care insurer or any state agency to provide coverage for the cost of any investigational drug, biologic, or device. III. Nothing in this chapter shall require the manufacture

Free access — add to your briefcase to read the full text and ask questions with AI

I. A manufacturer of an investigational drug, biologic, or device may make available an investigational drug, biologic, or device to eligible patients pursuant to this chapter. A manufacturer may:
(a) Provide an investigational drug, biologic, or device to an eligible patient without receiving compensation.
(b) Require an eligible patient to pay the costs of or associated with the manufacture of the investigational drug, biologic, or device.
(c) Require an eligible patient to participate in data collection relating to the use of the investigational drug, biologic, or device.
II. This chapter shall not require a health care insurer or any state agency to provide coverage for the cost of any investigational drug, biologic, or device.
III. Nothing in this chapter shall require the manufacturer of an investigational drug, biologic, or device to include an eligible patient in a particular clinical trial or study.
[Paragraph IV effective January 1, 2026.]
IV. Nothing in this chapter shall require a health care provider, health care facility, or the manufacturer of an investigational drug, biological product, or device, to make an experimental treatment available to an eligible patient.